<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38344131</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2328-8957</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Open forum infectious diseases</Title><ISOAbbreviation>Open Forum Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022.</ArticleTitle><Pagination><StartPage>ofad674</StartPage><MedlinePgn>ofad674</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ofad674</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ofid/ofad674</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">We described the oral nirmatrelvir/ritonavir (NMV/r) and molnupiravir (MOV) uptake among a subgroup of highly vaccinated adults in a US national prospective cohort who were infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between 12/2021 and 10/2022.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We estimate antiviral uptake within 5 days of SARS-CoV-2 infection, as well as age- and gender-adjusted antiviral uptake prevalence ratios by antiviral eligibility (based on age and comorbidities), sociodemographic characteristics, and clinical characteristics including vaccination status and history of long coronavirus disease 2019 (COVID).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">NMV/r uptake was 13.6% (95% CI, 11.9%-15.2%) among 1594 participants, and MOV uptake was 1.4% (95% CI, 0.8%-2.1%) among 1398 participants. NMV/r uptake increased over time (1.9%; 95% CI, 1.0%-2.9%; between 12/2021 and 3/2022; 16.5%; 95% CI, 13.0%-20.0%; between 4/2022 and 7/2022; and 25.3%; 95% CI, 21.6%-29.0%; between 8/2022 and 10/2022). Participants age &#x2265;65 and those who had comorbidities for severe COVID-19 had higher NMV/r uptake. There was lower NMV/r uptake among non-Hispanic Black participants (7.2%; 95% CI, 2.4%-12.0%; relative to other racial/ethnic groups) and among individuals in the lowest income groups (10.6%; 95% CI, 7.3%-13.8%; relative to higher income groups). Among a subset of 278 participants with SARS-CoV-2 infection after 12/2021 who also had a history of prior SARS-CoV-2 infection, those with (vs without) a history of long COVID reported greater NMV/r uptake (22.0% vs 7.9%; <i>P</i> = .001). Among those prescribed NMV/r (n = 216), 137 (63%; 95% CI, 57%-70%) reported that NMV/r was helpful for reducing COVID-19 symptoms.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Despite proven effectiveness against severe outcomes, COVID-19 antiviral uptake remains low among those with SARS-CoV-2 infection in the United States. Further outreach to providers and patients to improve awareness of COVID-19 oral antivirals and indications is needed.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yanhan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-9703-4412</Identifier><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>McKaylee M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulkarni</LastName><ForeName>Sarah G</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Puzniak</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamparo</LastName><ForeName>Joann M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allen</LastName><ForeName>Kristen E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Thomas M</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qasmieh</LastName><ForeName>Saba A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grov</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6871-3531</Identifier><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Community Health and Social Sciences, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srivastava</LastName><ForeName>Avantika</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimba</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>John M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Pfizer, Inc., Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nash</LastName><ForeName>Denis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Implementation Science in Population Health (ISPH), City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, City University of New York (CUNY), New York, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P2C HD050924</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH3 AI133675</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Open Forum Infect Dis</MedlineTA><NlmUniqueID>101637045</NlmUniqueID><ISSNLinking>2328-8957</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHASING COVID Cohort study</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">awareness of antivirals</Keyword><Keyword MajorTopicYN="N">molnupiravir (MOV)</Keyword><Keyword MajorTopicYN="N">nirmatrelvir-ritonavir (NMV/r)</Keyword></KeywordList><CoiStatement>Potential conflicts of interest. D.N. receives consulting fees from Gilead Sciences and AbbVie. CUNY received research support from Pfizer during the conduct of this study that was paid directly to CUNY. D.N. is the Principal Investigator on the research grant to the City University of New York School of Public Health that provided support for this study. L.P., J.M.Z., K.E.A., T.M.P., and J.M.M. are employees of Pfizer and may hold stock or stock options with Pfizer. All other authors report no potential conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>12</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>12</Day><Hour>15</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>12</Day><Hour>4</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38344131</ArticleId><ArticleId IdType="pmc">PMC10854389</ArticleId><ArticleId IdType="doi">10.1093/ofid/ofad674</ArticleId><ArticleId IdType="pii">ofad674</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
Centers for Disease Control and Prevention . COVID Data Tracker weekly review. 2023. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html. Accessed April 6, 2023.</Citation></Reference><Reference><Citation>
Centers for Disease Control and Prevention . COVID Data Tracker. 2020. Available at: https://covid.cdc.gov/covid-data-tracker/. Accessed April 2, 2023.</Citation></Reference><Reference><Citation>Aburto JM, Tilstra AM, Floridi G, Dowd JB. Significant impacts of the COVID-19 pandemic on race/ethnic differences in US mortality. Proc Natl Acad Sci U S A 2022; 119:e2205813119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436308</ArticleId><ArticleId IdType="pubmed">35998219</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. COVID-19: Pfizer's Paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ 2021; 375:n2713.</Citation><ArticleIdList><ArticleId IdType="pubmed">34750163</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. . Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med 2022; 386:509&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8693688</ArticleId><ArticleId IdType="pubmed">34914868</ArticleId></ArticleIdList></Reference><Reference><Citation>
Food and Drug Administration . Fact sheet for healthcare providers: emergency use authorization for Paxlovid. Available at: https://www.fda.gov/media/165227/download. Accessed February 2024.</Citation></Reference><Reference><Citation>
Food and Drug Administration . Fact sheet for healthcare providers: Emergency Use Authorization for LagevrioTM (molnupiravir) capsules. Available at: https://www.fda.gov/media/155054/download. Accessed September 27, 2022.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. . Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med 2022; 386:1397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. FDA briefing document NDA# drug name: nirmatrelvir tablets and ritonavir tablets copackaged for oral use applicant: Pfizer Inc. Antimicrobial Drugs Advisory Committee Meeting. 2023. Available at: https://www.fda.gov/media/166197/download. Accessed May 30, 2023.</Citation></Reference><Reference><Citation>Aggarwal NR, Molina KC, Beaty LE, et al. . Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of Omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis 2023; 23:696&#x2013;705.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014040</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Joyce B, Plumb ID, et al. . Paxlovid associated with decreased hospitalization rate among adults with COVID-19&#x2014;United States, April-September 2022. MMWR Morb Mortal Wkly Rep 2022; 71:1531&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9721144</ArticleId><ArticleId IdType="pubmed">36454693</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Dani SS, Ahmad J, et al. . Oral nirmatrelvir and ritonavir in non-hospitalized vaccinated patients with COVID-19. Clin Infect Dis 2022; 76:563&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9452095</ArticleId><ArticleId IdType="pubmed">35986628</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai C-C, Wang Y-H, Chen K-H, Chen C-H, Wang C-Y. The clinical efficacy and safety of anti-viral agents for non-hospitalized patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials. Viruses 2022; 14:1706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9415971</ArticleId><ArticleId IdType="pubmed">36016328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard JA, McLaughlin JM, Malden D, et al. . Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis 2023; 23:806&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10081864</ArticleId><ArticleId IdType="pubmed">36933565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema KL, Berry K, Streja E, et al. . Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. veterans: target trial emulation studies with one-month and six-month outcomes. Ann Intern Med 2023; 176:807&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243488</ArticleId><ArticleId IdType="pubmed">37276589</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler CC, Hobbs FDR, Gbinigie OA, et al. . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet 2022; 401:281&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9779781</ArticleId><ArticleId IdType="pubmed">36566761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gbinigie O, Ogburn E, Allen J, et al. . Platform adaptive trial of novel antivirals for early treatment of COVID-19 in the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease. BMJ Open 2023; 13:e069176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10407406</ArticleId><ArticleId IdType="pubmed">37550022</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health and Human Services. Test to Treat. Available at: https://aspr.hhs.gov/TestToTreat/Pages/default.aspx. Accessed April 3, 2023.</Citation></Reference><Reference><Citation>The White House. Fact sheet: Biden administration announces launch of first federally-supported Test to Treat site. 2022. Available at: https://www.whitehouse.gov/briefing-room/statements-releases/2022/05/26/fact-sheet-biden-administration-announces-launch-of-first-federally-supported-test-to-treat-site/. Accessed October 10, 2022.</Citation></Reference><Reference><Citation>Gold JAW, Kelleher J, Magid J, et al. . Dispensing of oral antiviral drugs for treatment of COVID-19 by zip code-level social vulnerability&#x2014;United States, December 23, 2021-May 21, 2022. MMWR Morb Mortal Wkly Rep 2022; 71:825&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">35737571</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MM, Kulkarni SG, Rane M, et al. . Cohort profile: a national, community-based prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA&#x2014;the CHASING COVID cohort study. BMJ Open 2021; 11:e048778.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458000</ArticleId><ArticleId IdType="pubmed">34548354</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson MM, Shamsunder MG, Brazier E, et al. . Racial/ethnic disparities in exposure, disease susceptibility, and clinical outcomes during COVID-19 pandemic in national cohort of adults, United States. Emerg Infect Dis 2022; 28:2171&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9622253</ArticleId><ArticleId IdType="pubmed">36191624</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence ratios. BMC Med Res Methodol 2008; 8:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2292207</ArticleId><ArticleId IdType="pubmed">18307814</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521200</ArticleId><ArticleId IdType="pubmed">14567763</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasmieh SA, Robertson MM, Teasdale CA, et al. . The prevalence of SARS-CoV-2 infection and other public health outcomes during the BA.2/BA.2.12.1 surge, New York City, April&#x2013;May 2022. Commun Med (Lond). 2023; 3:92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313770</ArticleId><ArticleId IdType="pubmed">37391483</ArticleId></ArticleIdList></Reference><Reference><Citation>Dryden-Peterson S, Kim A, Kim AY, et al. . Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med 2023; 176:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9753458</ArticleId><ArticleId IdType="pubmed">36508742</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N, Klausner JD. Usage and awareness of antiviral medications for COVID-19 among individuals at risk for severe COVID-19, March 2021 to 1 August 2022. Clin Infect Dis 2022; 74:1887&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36069403</ArticleId></ArticleIdList></Reference><Reference><Citation>
Fitzsimmons EG. New York City will offer Paxlovid at mobile testing sites, a first in the U.S. The New York Times. June 6, 2022. Available at: https://www.nytimes.com/2022/06/30/nyregion/nyc-paxlovid-covid-treatment.html. Accessed October 13, 2022.</Citation></Reference><Reference><Citation>NYC Health. COVID-19: outpatient therapeutic information for providers. Available at: https://www1.nyc.gov/site/doh/covid/covid-19-providers-treatments.page. Accessed October 13, 2022.</Citation></Reference><Reference><Citation>Smith ER, Oakley EM. Geospatial disparities in federal COVID-19 test-to-treat program. Am J Prev Med 2023; 64:761&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9977692</ArticleId><ArticleId IdType="pubmed">37085247</ArticleId></ArticleIdList></Reference><Reference><Citation>
Department of Health, Social Care . Thousands more patients to access second ground-breaking antiviral. 2022. Available at: https://www.gov.uk/government/news/thousands-more-patients-to-access-second-ground-breaking-antiviral. Accessed April 3, 2023.</Citation></Reference><Reference><Citation>Equils O, Bakaj Berishaj A, Stice E, da Costa C. COVID-19 risk perception, cognitive dissonance, and vaccine hesitancy. Hum Vaccin Immunother 2023; 19:2180217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10026885</ArticleId><ArticleId IdType="pubmed">36852481</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai DBG, Shah A, Doubeni CA, Sia IG, Wieland ML. The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States. Clin Infect Dis 2021; 72:703&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337626</ArticleId><ArticleId IdType="pubmed">32562416</ArticleId></ArticleIdList></Reference><Reference><Citation>Carethers JM. Insights into disparities observed with COVID-19. J Intern Med 2021; 289:463&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325576</ArticleId><ArticleId IdType="pubmed">33164230</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowkwanyun M, Reed AL Jr. Racial health disparities and COVID-19&#x2014;caution and context. N Engl J Med 2020; 383:201&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32374952</ArticleId></ArticleIdList></Reference><Reference><Citation>Nash D, Rane MS, Robertson MM, et al. . Severe acute respiratory syndrome coronavirus 2 incidence and risk factors in a national, community-based prospective cohort of US adults. Clin Infect Dis 2023; 76:e375&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213857</ArticleId><ArticleId IdType="pubmed">35639911</ArticleId></ArticleIdList></Reference><Reference><Citation>A decentralized, randomized phase 2 efficacy and safety study of nirmatrelvir/ritonavir in adults with long COVID. Available at: https://clinicaltrials.gov/ct2/show/NCT05668091?%20cond=Long+COVID&amp;draw=2&amp;rank=2. Accessed April 3, 2023.</Citation></Reference><Reference><Citation>SARS CoV-2 Viral Persistence Study (PASC)&#x2013;study of long COVID-19&#x2014;full text view. Clinicaltrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT05595369?%20type=Intr&amp;cond=Long+COVID&amp;draw=3&amp;rank=13. Accessed April 6, 2023.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post&#x2013;COVID-19 condition. JAMA Intern Med 2023; 183:554.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. Pfizer reports additional data on PaxlovidTM supporting upcoming new drug application submission to U.S. FDA. Available at: https://www.Pfizer.com/news/press-release/press-release-detail/pfizer-reports-additional-data-paxlovidtm-supporting. Accessed May 30, 2023.</Citation></Reference><Reference><Citation>Food and Drug Administration. Office of the Commissioner . Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. Available at: https://www.Fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19. Accessed December 19, 2022.</Citation></Reference><Reference><Citation>Drug interactions. Available at: https://paxlovid.pfizerpro.com/drug-interactions. Accessed November 13, 2023.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>